SCHEMBL21853773

SCHEMBL21853773

N[C@H](C(=O)O)[C@H](O)CCOCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 4/20 0.54
SLC1A3 P43003 3/20 0.54
SLC1A2 P43004 3/20 0.54
CYP2C19 P33261 2/20 0.54
MEN1 O00255 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
KMT2A Q03164 1/20 0.54
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
FOLH1 Q04609 1/20 0.44
TSHR P16473 1/20 0.42
ALPI P09923 1/20 0.42
PKM P14618 1/20 0.42
PTGS1 P23219 1/20 0.42
XIAP P98170 1/20 0.42
SLC7A5 Q01650 1/20 0.42
CA1 P00915 3/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5286295 1.00 SLC1A1 (0.54) SLC1A1SLC1A3SLC1A2CYP2C19MEN1
SCHEMBL8430055 0.91 SLC1A1 (0.51) SLC1A1SLC1A3SLC1A2CYP2C19MEN1
SCHEMBL8836900 0.91 SLC1A1 (0.51) SLC1A1SLC1A3SLC1A2CYP2C19MEN1
SCHEMBL8722230 0.84 CYP2C19 (0.47) SLC1A1SLC1A3SLC1A2CYP2C19MEN1
SCHEMBL8836944 0.84 SLC1A1 (0.59) SLC1A1SLC1A3SLC1A2CYP2C19MEN1
SCHEMBL8426348 0.84 SLC1A1 (0.59) SLC1A1SLC1A3SLC1A2CYP2C19MEN1
SCHEMBL27931897 0.84 SLC1A1 (0.59) SLC1A1SLC1A3SLC1A2CYP2C19MEN1
SCHEMBL6051430 0.82 SLC1A1 (0.65) SLC1A1SLC1A3SLC1A2CYP2C19MEN1
SCHEMBL6051426 0.82 SLC1A1 (0.65) SLC1A1SLC1A3SLC1A2CYP2C19MEN1
SCHEMBL27479686 0.82 SLC1A1 (0.65) SLC1A1SLC1A3SLC1A2CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3630795-B1 ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF ENZYMASTER NINGBO BIO ENG CO LTD (CN) 2023-07-26 EP disclosed
EP-3630795-B1 ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF ENZYMASTER NINGBO BIO ENG CO LTD (CN) 2023-07-26 EP disclosed
CN-110869383-B Engineered polypeptides and their use in the synthesis of beta-hydroxy-alpha-amino acids 宁波酶赛生物工程有限公司 2023-06-27 CN disclosed
CN-110914288-B Engineered aldolase polypeptides and uses thereof 宁波酶赛生物工程有限公司 2023-05-05 CN disclosed
US-11512303-B2 Engineered polypeptides and their applications in the synthesis of beta-hydroxy-alpha-amino acids ENZYMASTER (NINGBO) BIO-ENGINEERING CO., LTD. (CN) 2022-11-29 US disclosed
EP-3630798-B1 ENGINEERED ALDOLASE POLYPEPTIDES AND THEIR APPLICATIONS IN SYNTHESIS OF BETA-HYDROXY-ALPHA-AMINO ACIDS ENZYMASTER NINGBO BIO ENG CO LTD (CN) 2022-11-23 EP disclosed
US-11274287-B2 Engineered aldolase polypeptides and uses thereof Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) 2022-03-15 US disclosed
US-20210284987-A1 ENGINEERED POLYPEPTIDES AND THEIR APPLICATIONS IN THE SYNTHESIS OF BETA-HYDROXY-ALPHA-AMINO ACIDS ENZYMASTER (NINGBO) BIO-ENGINEERING CO., LTD. (CN) 2021-09-16 US disclosed
US-20200123525-A1 ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) 2020-04-23 US disclosed
US-20200123525-A1 ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) 2020-04-23 US disclosed
CN-110914288-A Engineered aldolase polypeptide and application thereof 宁波酶赛生物工程有限公司 2020-03-24 CN disclosed
CN-110869383-A Engineered polypeptide and application thereof in synthesis of β -hydroxy- α -amino acid 宁波酶赛生物工程有限公司 2020-03-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11274287-B2 Engineered aldolase polypeptides and uses thereof DERA, ALDOA, TKT SLC1A1 372/4885SLC1A3 390/4885SLC1A2 279/4885
US-20200123525-A1 ENGINEERED ALDOLASE POLYPEPTIDES AND USES THEREOF DERA, ALDOA, TKT SLC1A1 372/4885SLC1A3 390/4885SLC1A2 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.